Institutional members access full text with Ovid®

Share this article on:

IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis

Unizony, Sebastian, MD; Kermani, Tanaz A., MD, MS

Section Editor(s): Gordon, Lynn K. MD, PhD; Horton, Jonathan MD, PhD

doi: 10.1097/WNO.0000000000000713
Bench to Bedside: PDF Only

Division of Rheumatology, Allergy and Immunology (SU), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and Division of Rheumatology (TAK), David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Address correspondence to Sebastian Unizony, MD, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 2C, Boston, MA 02114; E-mail: sunizony@mgh.harvard.edu

S. Unizony: Roche—GiACTA trial investigator; GSK—Scientific advisory board; Sanofi—Scientific advisory board; Galapagos—Consulting. T. A. Kermani: Roche—Consultant for GCA educational module by Med-IQ which received educational grant from Hoffmann-La Roche.

© 2018 by North American Neuro-Ophthalmology Society